Kilitch Drugs (India) Ltd. has notified the stock exchanges of an upcoming board meeting scheduled for Friday, May 15, 2026. The intimation was issued on May 7, 2026, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Board Meeting Agenda

The meeting of the Board of Directors will be convened to consider and approve the audited financial results of the company for the quarter and year ended March 31, 2026. The results will cover both standalone and consolidated financials, providing a comprehensive view of the company's performance for Q4FY26 and the full fiscal year.

Key details of the scheduled board meeting are outlined below:

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, read with the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, and the relevant circulars issued by BSE and NSE dated April 2, 2019, the company has implemented a trading window closure. The trading window has been closed with effect from April 1, 2026, and will reopen 48 hours after the financial results are disclosed to the stock exchanges.

The intimation was signed by Mukund Mehta, Managing Director, on behalf of Kilitch Drugs (India) Limited.

Kilitch drugs (India) Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling mandatory regulatory requirements under SEBI guidelines. The pharmaceutical company filed the certificate on 14th April, 2026, addressing dematerialisation processes for the quarter ended 31st March, 2026.

Regulatory Compliance Filing

The company submitted the certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018 to both BSE Limited and National Stock Exchange of India Limited. Managing Director Mukund Mehta signed the submission letter, which was digitally authenticated on 14th April, 2026.

Registrar Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's Registrar and Share Transfer Agent. The registrar provided confirmation on 3rd April, 2026, certifying compliance with dematerialisation requirements during the quarter.

The registrar confirmed that securities received from depository participants for dematerialisation during Q4FY26 were properly processed. All securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are traded.

Process Verification

MUFG Intime India confirmed several key compliance aspects:

• Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• Security certificates received were mutilated and cancelled after due verification by depository participants
• Names of depositories were substituted in the register of members as registered owners
• All processes adhered to regulatory timelines and requirements

Corporate Communication

The filing was addressed to corporate relationship departments of both stock exchanges, with copies sent to NSDL and CDSL. Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India, signed the registrar's confirmation certificate.

This quarterly filing demonstrates Kilitch Drugs (India) Limited's adherence to SEBI regulations governing depositories and participants, ensuring transparent and compliant dematerialisation processes for shareholders.